Resistance in the anti-angiogenic era

Nay-saying or a word of caution?

Christopher J. Sweeney, Kathy Miller, George W. Sledge

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The hope that anti-angiogenic therapy might be the panacea for cancer has not yet been realized. There are many possible reasons for this, including endothelial and tumor cell heterogeneity, the presence of survival factors within the tumor micro-environment, the problem of defining the best dose and schedule for anti-angiogenic therapies, and angiogenesis-independent regrowth of tumors. Once these problems are understood, we can begin to evaluate approaches to thwarting them. These could include combining anti-angiogenic therapies with chemotherapy, with other anti-angiogenic agents or with other biological therapies. Another approach would be to employ a particular agent or combination of agents that target processes crucial to the survival of a particular cancer.

Original languageEnglish
Pages (from-to)24-29
Number of pages6
JournalTrends in Molecular Medicine
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Neoplasms
Biological Therapy
Appointments and Schedules
Therapeutics
Endothelial Cells
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Resistance in the anti-angiogenic era : Nay-saying or a word of caution? / Sweeney, Christopher J.; Miller, Kathy; Sledge, George W.

In: Trends in Molecular Medicine, Vol. 9, No. 1, 01.01.2003, p. 24-29.

Research output: Contribution to journalArticle

Sweeney, Christopher J. ; Miller, Kathy ; Sledge, George W. / Resistance in the anti-angiogenic era : Nay-saying or a word of caution?. In: Trends in Molecular Medicine. 2003 ; Vol. 9, No. 1. pp. 24-29.
@article{ee0ba3b41eba40718e44192353804ba0,
title = "Resistance in the anti-angiogenic era: Nay-saying or a word of caution?",
abstract = "The hope that anti-angiogenic therapy might be the panacea for cancer has not yet been realized. There are many possible reasons for this, including endothelial and tumor cell heterogeneity, the presence of survival factors within the tumor micro-environment, the problem of defining the best dose and schedule for anti-angiogenic therapies, and angiogenesis-independent regrowth of tumors. Once these problems are understood, we can begin to evaluate approaches to thwarting them. These could include combining anti-angiogenic therapies with chemotherapy, with other anti-angiogenic agents or with other biological therapies. Another approach would be to employ a particular agent or combination of agents that target processes crucial to the survival of a particular cancer.",
author = "Sweeney, {Christopher J.} and Kathy Miller and Sledge, {George W.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S1471-4914(02)00007-2",
language = "English",
volume = "9",
pages = "24--29",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Resistance in the anti-angiogenic era

T2 - Nay-saying or a word of caution?

AU - Sweeney, Christopher J.

AU - Miller, Kathy

AU - Sledge, George W.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The hope that anti-angiogenic therapy might be the panacea for cancer has not yet been realized. There are many possible reasons for this, including endothelial and tumor cell heterogeneity, the presence of survival factors within the tumor micro-environment, the problem of defining the best dose and schedule for anti-angiogenic therapies, and angiogenesis-independent regrowth of tumors. Once these problems are understood, we can begin to evaluate approaches to thwarting them. These could include combining anti-angiogenic therapies with chemotherapy, with other anti-angiogenic agents or with other biological therapies. Another approach would be to employ a particular agent or combination of agents that target processes crucial to the survival of a particular cancer.

AB - The hope that anti-angiogenic therapy might be the panacea for cancer has not yet been realized. There are many possible reasons for this, including endothelial and tumor cell heterogeneity, the presence of survival factors within the tumor micro-environment, the problem of defining the best dose and schedule for anti-angiogenic therapies, and angiogenesis-independent regrowth of tumors. Once these problems are understood, we can begin to evaluate approaches to thwarting them. These could include combining anti-angiogenic therapies with chemotherapy, with other anti-angiogenic agents or with other biological therapies. Another approach would be to employ a particular agent or combination of agents that target processes crucial to the survival of a particular cancer.

UR - http://www.scopus.com/inward/record.url?scp=0037251744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037251744&partnerID=8YFLogxK

U2 - 10.1016/S1471-4914(02)00007-2

DO - 10.1016/S1471-4914(02)00007-2

M3 - Article

VL - 9

SP - 24

EP - 29

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 1

ER -